Skip to main content

Influenza, Human

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine
NCT02107807 | PHASE 3 | INTERVENTIONAL

Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18 through 60 years of age) and elderly (≥61 years of age) subjects with and without immunosuppressive conditions.

Trial Information
17 Sites
539 Participants
Recruiting
18 Years to 71 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

, Novartis Investigational Site
Darlinghurst,New South Wales,Australia,2010
, Novartis Investigational Site
Darlinghurst,New South Wales,Australia,2010
, Novartis Investigational Site
Merewether,New South Wales,Australia,2291
, Novartis Investiagtional Site
Würzburg,Bayern,Germany,97070
, Novartis Investigational Site
Rostock,Mecklenburg-Vorpommern,Germany,18057
, Novartis Investigational Site
Magdeburg,Sachsen-Anhalt,Germany,39120
, Novartis Investigational Site
Hamburg,Germany,39120
, Novartis Investigational Site
Fossacesia,Chieti,Italy,66022
, Novartis Investigational Site
Lanciano,Chieti,Italy,66034
, Novartis Investigational Site
Monza,Milan,Italy,20052
, Novartis Investigational Site
Aviano,Padova,Italy,33080
, Novartis Investigational Site
San Daniele del Friuli,Udine,Italy,33038
, Novartis Investigational Site
Chieti,Italy,66013
, Novartis Investigational Site
Chieti,Italy,66013
, Novartis Investigational Site
Milan,Italy,20127
, Novartis Investigational Site
Milan,Italy,20157
, Novartis Investigational Site
Parma,Italy,43100

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov